Remimazolam besylate versus propofol for long-term sedation during invasive mechanical ventilation: a pilot study

Table 1 Baseline characteristics of the patients

	Remimazolam (n = 30)	Propofol (n = 30)	P value
Age, years	60.0 (51.5–66.3)	64.0 (55.0–69.3)	0.437
Male	20 (66.7%)	20 (66.7%)	1.000
BMI, kg/m²	22.7 (3.2)	24.2 (2.8)	0.061
APACHE II score	12.0 (4.4)	11.3 (3.2)	0.445
SOFA score	7.2 (3.0)	5.7 (2.2)	0.028
Suspected or proven sepsis^a	21 (70.0%)	17 (56.7%)	0.284
Shock^b	18 (60.0%)	14 (46.7%)	0.301
Type of ICU admission			0.029
Medical	10 (33.3%)	2 (6.7%)
Surgical	14 (46.7%)	22 (73.3%)
Trauma	6 (20.0%)	6 (20.0%)
RASS score at enrollment	− 2.0 (− 3.0 to − 1.0)	− 2.0 (− 3.0 to − 1.0)	0.910
Time from ICU admission to drug initiation, h	30.0 (18.8–53.0)	32.5 (17.0–53.0)	0.641

Data are count (%), mean (SD) or median (interquartile range)
BMI body mass index, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, RASS Richmond Agitation and Sedation Scale
^aKnown or suspected infection with SOFA score ≥ 2
^bPatients with blood pressure maintained via infusions of vasopressor prior to start of study drug

ISSN: 1364-8535